What is the history of Alpha 1-antitrypsin deficiency?

Alpha 1-antitrypsin deficiency (AATD) was first identified in 1963 by Dr. Carl-Bertil Laurell and Dr. Sten Eriksson, who linked the absence of a specific serum protein to the development of pulmonary emphysema. Since this discovery, our understanding of Alpha 1-antitrypsin deficiency has shifted from viewing it merely as a lung disease to recognizing it as a systemic, genetically determined protein misfolding disorder that can also significantly impact the liver.

When was Alpha 1-antitrypsin deficiency first discovered?

The history of Alpha 1-antitrypsin deficiency began in 1963 at Malmö General Hospital in Sweden. Dr. Carl-Bertil Laurell and his colleague Sten Eriksson were studying serum protein electrophoresis patterns when they identified five patients who lacked the alpha-1 band. Remarkably, all five of these patients suffered from early-onset emphysema. This groundbreaking observation established the first direct link between a genetic protein deficiency and a chronic respiratory disease, fundamentally changing the medical community's perception of emphysema as a condition caused solely by external factors like smoking.

How has our understanding of Alpha 1-antitrypsin deficiency evolved?

In the decades following its discovery, the clinical profile of Alpha 1-antitrypsin deficiency expanded significantly. While initial research focused almost exclusively on the lungs, researchers later discovered that the liver is also a major site of disease. In 1969, Sharp et al. reported that children with Alpha 1-antitrypsin deficiency could present with severe neonatal hepatitis and cirrhosis. We now understand that the condition occurs because the mutant AAT protein (most commonly the Z-allele) misfolds and accumulates within the liver cells (hepatocytes), causing damage, while failing to reach the lungs to protect them from enzymes like neutrophil elastase.

What are the major milestones in treatment and research?

The management of Alpha 1-antitrypsin deficiency has seen significant progress, moving from symptomatic support to targeted protein replacement. Key milestones include:

• 1963: Initial discovery of the association between protein deficiency and emphysema.


• 1968: Identification of the PiZZ genotype as the most severe form of the disease.


• 1980s: Development of intravenous Alpha-1 protein augmentation therapy, which involves infusing purified human AAT protein to raise blood levels.


• 1990s-Present: Integration of advanced genetic testing and the development of clinical registries to better track patient outcomes.

How did patient advocacy change the landscape?

For many years, Alpha 1-antitrypsin deficiency was frequently misdiagnosed as chronic obstructive pulmonary disease (COPD) caused by smoking, leading to significant patient isolation. The formation of patient advocacy groups, such as the Alpha-1 Foundation, was instrumental in shifting the narrative. These organizations have successfully lobbied for newborn screening programs, increased funding for research, and provided a platform for the 339 members of the DiseaseMaps.org community to share their experiences and reduce the stigma often associated with lung disease.

How does modern genetics inform current care?

Modern genomic technology has revolutionized how we identify individuals with Alpha 1-antitrypsin deficiency. We now have a precise understanding of the SERPINA1 gene located on chromosome 14, which encodes the AAT protein. Today, DNA sequencing allows for the rapid identification of various alleles, enabling family screening and early intervention. This genetic precision is critical, as it helps distinguish between carriers (who may have mild risks) and those with severe deficiencies who require proactive monitoring of both lung and liver health.

Next steps

• Consult a pulmonologist or hepatologist specializing in AATD to discuss your specific genotype.


• Request a baseline assessment of your lung function (spirometry) and liver health (blood tests/imaging).


• Connect with the 339 members on DiseaseMaps.org to find peer support and shared experiences.


• Discuss family cascade screening with a genetic counselor to protect at-risk relatives.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Alpha-1 antitrypsin deficiency.


• Orphanet: Alpha-1 antitrypsin deficiency (ORPHA:73).


• OMIM (Online Mendelian Inheritance in Man): SERPINA1 gene entry.


• The Alpha-1 Foundation: Historical archives and patient resources.